Overview

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.
Phase:
N/A
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Antidepressive Agents
Fluoxetine
Milnacipran
Mirtazapine
Nortriptyline
Paroxetine
Sertraline
Venlafaxine Hydrochloride